Financial Report: Sanofi

Sanofi
3Q Revenues: €9.1 billion (flat)
3Q Earnings: €2.9 billion (-1%)
YTD Revenues: €26.4 billion (+6%)
YTD Earnings: €7.7 billion (+7%)
Comments: Pharmaceuticals sales were up 3% to €7.1 billion in the quarter. Sanofi Genzyme sales were up 14% at CER to €1.4 billion due to the strong U.S. launch of Dupixent and growth in Multiple Sclerosis. Lantus sales were €867 million, down 25%. Toujeo sales were up 9% to €179 million. Cerezyme sales were down 6% to €119 million. Myozyme sales were €166 million, up 4%. Fabrazyme sales were up 4% to €158 million. Diabetes and Cardiovascular sales declined 15% to €1.3 billion. Plavix sales were down 11% to €358 million. Lovenox sales were down 8% to €370 million. Renagel sales were down 38%. Sanofi Pasteur grew 11% to €1.9 billion at CER driven by pediatric combinations and booster vaccines. Polio/Pertussis/Hib sales were up 34% to €433 million. Influenza vaccine sales were €951 million down 4%. Meningitis/Pneumonia sales were €252 million, down 1%. Adult booster sales were up 38% to €143 million.